Skip to main content

Advertisement

Table 2 Best overall response according to RECIST

From: Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR

Parameter PCG arm (%) (N = 43) PC arm (%) (N = 43) Odds ratio (95 % CI) P-value
Objective response 18 (41.9) 17 (39.5) 0.91 0.826
95 % CI (27.0–57.9) (25.0–55.6) (0.38–2.13)  
Disease control 32 (74.4) 28 (65.1) 0.64 0.348
95 % CI (58.8–86.5) (49.1–79.0) (0.25–1.61)  
Complete response 0 (0) 0 (0)   
Partial response 18 (41.9) 17 (39.5)   
Stable disease 14 (32.6) 11 (25.6)   
Progressive disease 10 (23.3) 13 (30.2)   
Missing 1 (2.3) 2 (4.7)   
  1. N number; CI confidence interval